Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- LATUDA Meets Efficacy Endpoints in 3rd PIII Trial
November 15, 2010
- Lurasidone Approval “Exceptionally Quick”: DSP President Tada
November 15, 2010
- Zyvox Shows Higher Success Rate than Vancomycin: Pfizer
November 15, 2010
- Applications Based on Data from Public Domain Recommended for 3 APIs by 2nd Committee
November 8, 2010
- Injectable Cravit Approved: Daiichi Sankyo
November 8, 2010
- Generics Show Big Differences in Market Share Depending on Therapeutic Category
November 8, 2010
- Price Settlement Not Expected before End December for 26.2% of Sales: NPhA
November 8, 2010
- 6 APIs Recommended for Application Based on Data from Public Domain by 1st Committee
November 8, 2010
- Astellas Applies for Degarelix in Japan
November 8, 2010
- tella, CreaGene Sign MOU to Jointly Develop Dendritic Cell Vaccine Therapy
November 8, 2010
- Takeda: Sales, Profits Down Due to Takepron Patent Expiration
November 8, 2010
- 14-Day Limit on Prescription of New Drugs to Be Relaxed for Combination Drugs
November 8, 2010
- Eli Lilly Applies for Bipolar Disorders for Zyprexa
November 8, 2010
- Daiichi Sankyo: Sales Up 6.0% Due to Recovery of Ranbaxy Business
November 8, 2010
- Chuikyo to Review Combinations of Insurance-Covered, Non-Covered Healthcare Services
November 8, 2010
- MSD Applies for Coadministration of Sitagliptin, Insulin
November 8, 2010
- Eisai: Record-High Profits Driven by Aricept
November 8, 2010
- Korosho to Take Advantage of Kohdo-Iryo System to Eliminate Drug Lag
November 8, 2010
- Chugai Applies for Pegasys, Copegus Combination Therapy
November 8, 2010
- MTPC: Remicade Drives Business with 29% Increases in Sales
November 8, 2010
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…